News from Aeon Scientific
CE Mark for Aeon Phocus granted
Aeon Scientific has received the CE Mark approval for the Aeon Phocus™, a robotic system to steer ablation catheters for the treatment of cardiac arrhythmias.
Aeon Scientific is pleased to announce that it has received the CE Mark approval for the Aeon Phocus™, an electromagnetic system to steer ablation catheters for the treatment of cardiac arrhythmias. More than one in a hundred people are affected by cardiac arrhythmias. The product is now available throughout Europe where more than one thousand clinics currently perform cardiac ablation procedures.
“CE mark approval of the Aeon Phocus is a major milestone for Aeon Scientific”, stated Dominik Bell, CEO of Aeon Scientific. “With our product we want to improve ablation procedures that a quarter of a million patients per year undergo in Europe. We are now excited to see how the result of our efforts can be put to use and help to improve outcomes for many patients.”
The system supports electrophysiologists during catheter ablation procedures for the treatment of cardiac arrhythmias, such as Atrial Fibrillation. It allows the physician to move the ablation catheter within the heart of the patient with magnetic fields. With the improved control and the high intuitiveness and dexterity that the system provides the company intends to improve procedures for the benefit of patients and healthcare providers. In the long-term it is the company’s objective to turn the Aeon Phocus into a platform for remotely controlling multiple types of interventional instruments such as catheters, guide wires and endoscopes.